Dr. Robert A. Mittra, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Duke University School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 968
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Duke University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
MN license 42976
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Vitreoretinal Surgery PLLC (23 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 968
- Services billed
- 25,894
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 5,340 | 19 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 3,068 | 176 |
| Imaging of retina | 2,960 | 982 |
| Injection, aflibercept, 1 mg | 2,164 | 214 |
| Injection of drug into eye | 1,900 | 447 |
| Injection, ranibizumab, 0.1 mg | 1,300 | 119 |
| Established patient complete exam of visual system | 895 | 637 |
| Established patient problem focused exam of visual system | 291 | 208 |
| Unclassified biologics | 278 | 44 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 207 | 180 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Minneapolis, MN | 303 |
| Ketorolac Tromethamine Other prescribers in Minneapolis, MN | 197 |
| Polymyxin B Sul-Trimethoprim (polymyxin b sulf/trimethoprim) | 152 |
| Latanoprost Other prescribers in Minneapolis, MN | 45 |
| Dexamethasone Sodium Phosphate | 42 |
| Dorzolamide Hcl Other prescribers in Minneapolis, MN | 30 |
| Brimonidine Tartrate Other prescribers in Minneapolis, MN | 24 |
| Timolol Maleate Other prescribers in Minneapolis, MN | 14 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Minneapolis, MN | 13 |
| Spironolactone Other prescribers in Minneapolis, MN | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $2,940 in total to this clinician.
| Genentech USA, Inc. | $2,940 |
|---|
| Consulting Fee | $2,925 |
|---|---|
| Food and Beverage | $15.42 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Apr 11, 2025 | Consulting Fee Susvimo · Immunology and Ophthalmology | $2,925 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 4 companies. The companies reported $1,127,010 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - Port Delivery System of Ranibizumab Extension Study
Genentech, Inc. - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - Entry into human of RO7497372 in participants with diabetic macular edema
Roche Tcrc, Inc. - MAD to assess the safety tolerability and PK PD in nAMD patients
Genentech, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere)
Genentech, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Bayer HealthCare Pharmaceuticals Inc. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - Port Delivery System for Ranibizumab
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.